Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 6/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.66 |
| ▸ | MC5R | P33032 | 1/20 | 0.66 |
| ▸ | MC3R | P41968 | 1/20 | 0.66 |
| ▸ | MC1R | Q01726 | 1/20 | 0.66 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.66 |
| ▸ | GCGR | P47871 | 3/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | NPY4R | P50391 | 1/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.62 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462886 | 0.96 | MC4R (0.68) | GLP1RMC4RMC5RMC3RMC1R | |
| SCHEMBL29397826 | 0.95 | CXCL8 (0.64) | GLP1RMC4RMC5RMC3RMC1R | |
| SCHEMBL31332244 | 0.95 | CXCL8 (0.64) | GLP1RMC4RMC5RMC3RMC1R | |
| SCHEMBL29874649 | 0.93 | MC4R (0.69) | GLP1RMC4RMC5RMC3RMC1R | |
| Dynorphin A (1-17) SCHEMBL31331988 | 0.90 | NPY1R (0.68) | GLP1RCXCR4IL23RC5AR1NPY1R | |
| Dynorphin A (1-17) SCHEMBL30248363 | 0.90 | NPY1R (0.68) | GLP1RCXCR4IL23RC5AR1NPY1R | |
| SCHEMBL30495798 | 0.90 | NPY1R (0.68) | GLP1RMC4RMC5RMC3RMC1R | |
| SCHEMBL29389654 | 0.90 | MC4R (0.67) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL30432613 | 0.90 | NPY1R (0.69) | GLP1RMC4RMC5RMC3RMC1R | |
| SCHEMBL29545955 | 0.89 | KEAP1 (0.69) | GLP1RMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270313-A1 | CLDN18.2 ANTIBODY AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250179124-A1 | BETA-CATENIN PROTEIN DEGRADATION | UBIQUITX (US) | 2025-06-05 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| CN-119591667-A | Short peptide for treating neonatal bacterial meningitis and preparation method thereof | 中国医科大学 | 2025-03-11 | — | — | CN | claimed |
| CN-119524018-A | Method for promoting growth of natural bezoar by using novel small molecular peptide combination | 北京永慧互赢科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-12214078-B2 | Artificial beta cells and methods of use thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2025-02-04 | — | — | US | claimed |
| EP-4476268-A2 | BETA-CATENIN PROTEIN DEGRADATION | Ubiquitx (US) | 2024-12-18 | — | — | EP | claimed |
| CN-115124604-B | Recombinant antibacterial peptide E-EJ97, recombinant expression vector, engineering bacteria and application thereof | 中国海洋大学 | 2024-06-04 | — | — | CN | claimed |
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | PROLYNX LLC (US) | 2024-02-08 | — | — | US | claimed |
| CN-117491645-A | Method for determining interleukin-6 based on peptide isotope dilution mass spectrum | 南京市计量监督检测院 | 2024-02-02 | — | — | CN | claimed |
| EP-4151227-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-22 | — | — | EP | claimed |
| CN-115827791-A | Glycopeptide parallel identification method based on multi-database spectrogram clustering | 深圳登鼎医药科技有限公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4108676-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-115124604-A | Recombinant antibacterial peptide E-EJ97, recombinant expression vector, engineering bacterium and application thereof | 中国海洋大学 | 2022-09-30 | — | — | CN | claimed |
| US-11389405-B2 | Artificial beta cells and methods of use thereof | NORTH CAROLINA STATE UNIVERSITY (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022111633-A1 | CLDN18.2 ANTIBODY AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-02 | — | — | WO | claimed |
| WO-2022115563-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | PROLYNX LLC (US) | 2022-06-02 | — | — | WO | claimed |
| CN-110218283-B | Special superplasticizer for high and ultrahigh strength concrete and preparation method thereof | 江苏苏博特新材料股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-108796055-B | Method, device and storage medium for detecting tumor neoantigen based on second-generation sequencing | 深圳裕策生物科技有限公司 | 2022-04-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041982-A1 | EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES | NPPA, NPR1, NPR3 | GLP1R 20/4885MC4R 1288/4885MC5R 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.